Analysis posted August 2015
Kyprolis (carfilzomib) was granted accelerated FDA approval in July 2012 for the treatment of multiple myeloma. Its recently completed Phase III ASPIRE trial shows even better efficacy. Based on these newly reported clinical data, Kyprolis is highly innovative, as measured in Equinox Group’s framework, and we expect robust sales growth in the future.
The Drivers of Improvement chart shows a strong efficacy advantage in adding Kyprolis to lenalidomide + dexamethasone. The improvements in median overall survival, median progression-free survival, and overall response rate, along with the associated mortality and morbidity gains, more than offset the disadvantages of adding an intravenous therapy to an oral regimen, the increased side effects, and the additional costs. The Clinical Innovation of 14.5% indicates that Kyprolis in combination with lenalidomide + dexamethasone will become the standard of care for patients with multiple myeloma who have been treated with 1-3 prior therapies.